Biologic Drug Analytics
Manufacturing and QC
Biologics Manufacturing and QC
Early strategic approaches and the application of advanced analytics before critical stages can improve product development, manufacturing, and clinical outcomes. ProtaGene offers industry-leading strategies, state-of-the-art analytic platforms run under GMP quality systems, and specialized expertise across both Europe and the US to help advance your manufacturing and product-facing analytical programs such as:
-
Manufacturing and Process Analytics
-
Method Development
-
Phase Appropriate Validation
-
QC-lot Release
-
Stability Program Management
-
Analytical Life Cycle Management
-
Host Cell Protein Analysis
Analytical Solutions from Research to Market
Biologic Therapeutics Platform Expertise
Our deep experience advancing a diverse range of therapeutic platforms from research through market help the ProtaGene team design highly effective analytical programs that de-risk development and accelerate timelines to your next key milestones. Key biologic development areas include:
-
Recombinant proteins—including complex, highly glycosylated proteins
-
bullet Created with Sketch. Multi-subunit complexes—protein, nucleotide, ligand
-
bullet Created with Sketch. mAbs
-
bullet Created with Sketch. ADCs and protein conjugates
-
bullet Created with Sketch. PEGylated proteins
-
bullet Created with Sketch. Bispecifics/multispecifics
-
bullet Created with Sketch. Fusion proteins
-
bullet Created with Sketch. Enzyme replacement therapies
-
bullet Created with Sketch. Biosimilars
-
bullet Created with Sketch. Vaccines, including subunit/recombinant
Analytical Systems
Enabled by state-of-the-art technology, ProtaGene offers an extensive range of analytical capabilities to support your biotherapeutic or gene & cell therapy projects.